logo-loader

The RegMed Daily Dialogue - The June Swoon is ON

Last updated: 18:03 06 Jun 2011 BST, First published: 22:03 06 Jun 2011 BST

no_picture_pai

Regenerative medicine/stem cell universe is OFF marginally (from last week) and dropping  in mid-day trading so …  what is new … on Monday (6/6/11) – nothing!

The NASDAQ is DOWN -9.00 (-0.13%) to 2723.78. The Dow is also DOWN -16.35 (-0.13%) to 12,134.91. Being that macro initiatives have played such a major role, it is appropriate to mention:

A string of disappointing economic data capped by last week’s jobs report is prompting more optimistic questioning the durability of the US recovery.

  • While I still see growth strengthening in the months ahead, my past (last week) remarks have voiced concern that the lull in the economy affecting markets … may prove prolonged, leaving it more vulnerable to external shocks or policy missteps. The concern is that there’s enough weakness that could feed on itself;
  • US stocks fell today, Monday (6/6/11) as investors watch to see whether further support levels would be challenged.

WOW only … PSTI (+$0.04) is up … as I struggle for positive signs! 

What’s driving the regenerative medicine – stem cell market … today … there is NO relief from selling.

Geron (GERN) presents at the American Society of Clinical Oncology (ASCO)/American Association for Cancer Research (AACR) Joint Session: Telomeres and Telomerase in Cancer. Presenting will be Kathy D. Miller, MD, Associate Professor and Sheila D. Ward Scholar at the Indiana University Melvin and Bren Simon Cancer Center and lead investigator of GERN’s ongoing P2 clinical trial of the telomerase inhibitor drug, imetelstat, in patients with breast cancer. The presentation is titled “The Clinical Perspective: Where We Are Going with Telomeres and Telomerase”. The bottom line, today’s joint ASCO/AACR session once again highlights the importance of telomerase as a target for developing novel cancer therapies. GERN’s P2 clinical program for imetelstat includes 4 clinical trials – 2 randomized clinical trials in non-small cell lung cancer and breast cancer, and 2 smaller single arm studies in multiple myeloma and essential thrombocythemia. These trials focus on malignancies in which cancer stem cells are believed to play an important role in disease progression and relapse after standard therapy.

Fresenius Biotech’s ATG-Fresenius S Use Approved in Austria: Fresenius SE & Co. KGaA said its Fresenius Biotech unit had received approval from the Austrian Federal Office for Safety in Health Care for the use of its polyclonal antibody ATG-Fresenius S in stem cell transplantations. The bottom line, Austria is the 5th country to approve the preparation in this indication, after Germany, Argentina, Portugal and Thailand.

UK regulators approve collection, storage of adult stem cells: The U.K.’s Human Tissue Authority has given the go-ahead to a stem cell collection service called Oristem to collect and store stem cells from adults. Stem cell services previously could collect stem cells from only newborns. Stored stem cells potentially may be used to treat various diseases. https://www.telegraph.co.uk/science/science-news/8556764/Blood-stem-cell-bank-to-provide-biological-insurance-for-adults.html . The bottom line, currently NO stem cell therapies exist that can use these types of cells for treating diseases. As researchers develop new techniques and new technology, it might be possible to use these stem cells for treating diseases.

 

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

49 minutes ago